WO2017221012A1 - Méthodes et compositions pour prévenir ou réduire, le risque de cardiotoxicité liée aux traitements du cancer. - Google Patents

Méthodes et compositions pour prévenir ou réduire, le risque de cardiotoxicité liée aux traitements du cancer. Download PDF

Info

Publication number
WO2017221012A1
WO2017221012A1 PCT/GB2017/051821 GB2017051821W WO2017221012A1 WO 2017221012 A1 WO2017221012 A1 WO 2017221012A1 GB 2017051821 W GB2017051821 W GB 2017051821W WO 2017221012 A1 WO2017221012 A1 WO 2017221012A1
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
reducing
compound
pharmaceutically acceptable
receptor agonist
Prior art date
Application number
PCT/GB2017/051821
Other languages
English (en)
Inventor
Björn DAHLÖF
Anders Ljunggren
Necip ERMIS
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of WO2017221012A1 publication Critical patent/WO2017221012A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to a new use of compounds that are angiotensin II (Ang II) agonists, more particularly selective agonists of the Ang II type 2 receptor (hereinafter the AT2 receptor), and especially agonists that bind selectively to that receptor, for prevention/reduction of risk/reduction of severity/reduction of the occurrence of cancer treatm e nt- re I ated ca rd i otoxi ci ty .
  • Ang II angiotensin II
  • AT2 receptor selective agonists of the Ang II type 2 receptor
  • Cancer treatment-related cardiotoxicity can occur as a consequence of direct effects on cardiac myocytes (function or protective mechanisms) and may include damage to the vascular endothelium, hemodynamic flow alterations and thrombotic events. Cardiotoxicity presents acutely during cancer treatment, potentially limiting dose and reducing the effectiveness of cancer treatment, and decades after treatment, leading to early mortality due to accelerated treatment-induced heart disease.
  • Anti-cancer treatments associated with cardiovascular risk include cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation, all of which have different anti-tumor mechanisms and on- and off-target effects that will influence what type of cardiac damage occurs. While mechanisms contributing to cardiotoxicity for selected agents have been proposed, few have been explored in the clinical setting for translation into effective prediction, prevention, detection and management methods for cancer treatment- related cardiotoxicity during cancer treatment and survivorship care. The discovery and increasing use of molecularly targeted cancer therapies, multi-modality treatments, and multidrug regimens for cancer treatment has widened this knowledge gap and changed the profile of cardiotoxicity in terms of timing and presentation.
  • Candesartan is an Angiotensin II type 1 (AT1) receptor antagonist, which selectively binds to and blocks the AT1 receptor of the Renin-Angiotensin System, RAS.
  • AT1 Angiotensin II type 1
  • RAS Renin-Angiotensin System
  • Compounds of the invention are agonists of angiotensin II (Ang II), more particularly, are agonists of the AT2 receptor, and, especially, are selective agonists of that sub-receptor.
  • the compounds of the invention are those that can stimulate AT2 receptors.
  • a method for preventing/reducing the risk of/reducing the occurrence of/ reducing the severity of cardiotoxicity associated with cancer treatment in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a composition comprising at least one angiotensin II receptor agonist, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • the at least one angiotensin II receptor agonist can be a selective agonist of an angiotensin II type 2 (AT2) receptor.
  • the at least one angiotensin II receptor agonist can be an angiotensin II type 2 (AT2) receptor agonist, and is preferably A/-butyloxycarbonyl-3-(4- imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • the at least one angiotensin II receptor agonist may be administered with at least one other angiotensin II receptor agonist, at least one angiotensin II type 1 (AT1) receptor antagonist and/or at least one angiotensin converting enzyme (ACE) inhibitor.
  • AT2 angiotensin II type 2
  • ACE angiotensin converting enzyme
  • angiotensin II receptor agonists and more particularly agonists of the angiotensin II type 2 receptor (the AT2 receptor), and especially agonists that bind selectively to that receptor, are of use in the treatment and/or prevention/reduction of the risk of/reduction of the occurrence of/reduction of the severity of cancer treatment-related cardiotoxicity when the AT2 receptor agonist is administered to the subject in need.
  • compounds of the invention e.g., AT2 receptor agonists or compounds that stimulate AT2 receptors
  • pharmaceutically acceptable salts, solvates or prodrugs thereof can be used for prevention/reduction of the risk of/reduction of the occurrence of/reduction of the severity of cancer treatment-related cardiotoxicity.
  • a compound of the invention can be A/-butyloxycarbonyl-3-(4-imidazol-1- ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (Compound 21 or, in short, C21), or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • Compounds of the invention may also be administered in combination with other AT2 agonists that are known in the art, as well as in combination with AT1 receptor antagonists that are known in the art, and/or in combination with an inhibitor of angiotensin converting enzyme (ACE).
  • ACE angiotensin converting enzyme
  • a method for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity comprises administration of a therapeutically effective amount of a compound of the invention (or a pharmaceutically acceptable salt, solvate or prodrug thereof) to a subject suffering from cancer.
  • a method comprising administration of a therapeutically effective amount of a compound of the invention (or a pharmaceutically acceptable salt, solvate or prodrug thereof) to a subject suffering from cancer, before, during and/or after initiation of the cancer treatment.
  • composition comprising at least one angiotensin II receptor agonist (e.g. an angiotensin II type 2 (AT2) receptor agonist), and/or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, for use in preventing/reducing the risk of/reducing the occurrence of/ reducing the severity of cardiotoxicity associated with cancer treatment.
  • angiotensin II receptor agonist e.g. an angiotensin II type 2 (AT2) receptor agonist
  • compounds of the invention may also be used in the manufacture of a medicament for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • the compound can be A/-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt, solvate or prodrug thereof, which may be used in the manufacture of a medicament for the prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • a method for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity comprises administering a compound of the invention (e.g., an AT2 receptor agonist or other compound that stimulates an AT2 receptor, or a pharmaceutically acceptable salt, solvate or prodrug thereof) to a subject in need of such prevention/reduction of the risk/reduction of the occurrence/reduction of the severity.
  • a method for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity comprises administering (e.g.
  • Effective amount refers to an amount of a compound, composition and/or formulation of the invention that is sufficient to produce a desired effect, which can be a therapeutic and/or beneficial effect.
  • the effective amount will vary with the age, general condition of the subject, the severity of the condition being treated, the particular agent administered, the duration of the treatment, the nature of any concurrent treatment, the pharmaceutically acceptable carrier used, and like factors within the knowledge and expertise of those skilled in the art.
  • an "effective amount” in any individual case can be determined by one skilled in the art by reference to the pertinent texts and literature and/or by using routine experimentation.
  • treat By the term “treat,” “treating,” or “treatment of” (and grammatical variations thereof) it is meant that the severity of the subject's condition is reduced, at least partially improved or ameliorated and/or that some alleviation, mitigation or decrease in at least one clinical symptom is achieved and/or there is a delay in the progression of the disease or disorder.
  • prevent refers to a delay in the extent or severity of a disease, disorder and/or clinical symptom(s) after onset relative to what would occur in the absence of carrying out the methods of the invention prior to the onset of the disease, disorder and/or clinical
  • the prevention can be complete, e.g., the total absence of the disease, condition and/or clinical symptom(s).
  • the prevention can also be partial, such that the occurrence of the disease, disorder and/or clinical symptom(s) in the subject and/or the severity of onset is less than what would occur in the absence of the present invention.
  • preventing can mean reducing the risk of cardiotoxicity associated with cancer treatment.
  • a “therapeutically effective” amount as used herein is an amount that is sufficient to treat (as defined herein) the subject.
  • a “therapeutically effective” amount as used herein is an amount that is sufficient to achieve the reduction or prevention specified herein.
  • a "subject" of the invention can include, but is not limited to, a mammalian subject.
  • the subject can be a human subject, a rodent subject (such as a mouse, a rat, or a hamster), or a domesticated animal subject (such as a dog, a cat, a pig, cattle, a sheep, a goat, a chicken, or a rabbit).
  • the subject is a human.
  • a "subject in need” of the methods of the invention can be a subject known to have or suspected of having cancer and at risk for treatment-related cardiotoxicity. Such subject in need is exemplified below, but not limited to:
  • one or more compounds of the invention as a cardioprotective agent, with or without an AT1 receptor antagonist and/or an ACE inhibitor either before, during or after initiation of effective cancer therapy, the inclusion criteria for such therapy can be widened.
  • a patient having a slight deterioration of heart function after initiation of effective cancer therapy Such a condition often leads to reduced doses of the cancer therapy and possibly less effective cancer treatment.
  • Concomitant treatment with a compound of the invention, with or without an AT1 receptor antagonist and/or an ACE inhibitor, may allow effective cancer therapy doses to be kept unchanged in many cancer patients.
  • a patient undergoing radiation therapy to treat cancer Radiation therapy is frequently used to treat certain patients with cancers of the lung, of the esophagus or of the breast. Such therapy is sometimes combined with cytostatic agents. If the tumors are located close to the heart, the risk for cardiotoxic radiation effects increases, and may result in enhanced formation of fibrosis in the myocardium or in the valves, leading to decreased cardiac function. By treatment with a compound of the invention, the risk for chronic radiation damage to the heart may be reduced.
  • concomitant administration or “combination administration” of a compound, therapeutic agent or known drug with a compound of the present invention means administration of a known medication or drug and, in addition, the one or more compounds of the invention to the same subject at such time that both the known drug and the compound will have a therapeutic effect. In some cases this therapeutic effect will be synergistic.
  • Such concomitant administration can involve concurrent (i.e., at the same time), prior, or subsequent administration of the known drug with respect to the administration of a compound of the present invention.
  • a person skilled in the art would have no difficulty determining the appropriate timing, sequence and dosages of administration for particular drugs and compounds of the present invention.
  • the compounds of this invention will be used, either alone or in combination with each other or in combination with one or more other therapeutic medications as described herein, or their pharmaceutically acceptable salts, solvates or prodrugs, for manufacturing a medicament for the purpose of providing for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • other therapeutic medications include: an angiotensin II type 1 (AT1) receptor antagonist (such as candesartan); or an inhibitor of angiotensin converting enzyme (ACE).
  • AT1 angiotensin II type 1 receptor antagonist
  • ACE angiotensin converting enzyme
  • renin a protease
  • angiotensinogen cleaves its only known substrate (angiotensinogen) to form angiotensin I, which in turn serves as substrate for angiotensin converting enzyme (ACE) to form Ang II.
  • ACE angiotensin converting enzyme
  • the endogenous hormone Ang II is a linear octapeptide (Asp 1 -Arg 2 -Val 3 -Tyr 4 -lle 5 -His 6 -Pro 7 -Phe 8 ), and is an active component of the renin-angiotensin system (RAS).
  • AT1 angiotensin II type 1 receptor
  • the AT2 receptor has also been shown to be involved in apoptosis and inhibition of cell proliferation (de Gasparo M et al. Pharmacol Rev 2000; 52:415-472).
  • AT2 receptor agonists have been shown to be of potential utility in the treatment and/or prophylaxis of disorders of the alimentary tract, such as dyspepsia and irritable bowel syndrome, as well as multiple organ failure (see international patent application WO 99/43339).
  • agonism of the AT2 receptor The expected pharmacological effects of agonism of the AT2 receptor are described in general in de Gasparo M et al., Pharmacol Rev 2000; 52:415-472. However, it is not mentioned that agonism of the AT2 receptor may be used for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • AT2 The effects of Ang II on cell growth, inflammation and extracellular matrix synthesis are mainly coupled to AT1 , whereas the function of AT2 has been heavily investigated and new research indicates that it is more prevalent in damaged tissue and exerts reparative properties and properties opposing the AT1 receptor.
  • the AT2 receptor has been shown to be important in reducing myocyte hypertrophy and fibrosis.
  • AT2 receptor agonists have also been described, for instance, in international patent application WO 2002/096883. However, these compounds were not suggested for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity. No clinical trials have so far been initiated with an agonist of the AT2 receptor to evaluate possible cardioprotective effects in patients diagnosed with cancer and subjected to cancer therapies.
  • Anthracyclines may have the cardiovascular manifestations of LVD (left ventricular dysfunction), HF (heart failure), myocarditis, or arrhythmia.
  • 5- Fluorourcil may have the cardiovascular manifestations of ischemia, HF, pericarditis, or cardiogenic shock. Taxanes (e.g.
  • paclitaxel and vinca alkaloids may have the cardiovascular manifestations of Sinus bradicardia, ventricular tachycardia, atrioventricular block, HF, or ischemia.
  • Cyclophoshamide may have the cardiovascular manifestations of HF (neurohumoral activation), or mitral regurgitation.
  • Trastuzumab may have the cardiovascular manifestations of HF, LVD, or arrhythmia.
  • Tamoxifen may have the cardiovascular manifestations of thromboembolism, or cholesterol metabolism anomalies.
  • Bevacizumab may have the cardiovascular manifestations of hypertension, or thromboembolism.
  • COX-2 specific inhibitors may have the cardiovascular manifestations of thromboembolism. Further manifestations may for example include diastolic dysfunction and valvular insufficiency.
  • the cancer treatment-related cardiotoxicity includes one or more symptoms selected from the group consisting of LVD (left ventricular dysfunction), HF (heart failure), myocarditis, arrhythmia, ischemia, pericarditis, cardiogenic shock, Sinus bradicardia, ventricular tachycardia, atrioventricular block, mitral regurgitation, thromboembolism, cholesterol metabolism anomalies, hypertension, diastolic dysfunction and valvular insufficiency.
  • the cancer treatment-related cardiotoxicity is LVD or heart failure.
  • an AT2 receptor agonist or a compound that stimulates AT2 receptors
  • a pharmaceutically acceptable salt preferably an HCI salt of a compound of the invention
  • solvate or prodrug thereof for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • such AT2 receptor agonists and/or compounds that stimulate AT2 receptors may be referred to herein as the "compounds of the invention”.
  • a compound of the invention can include, but is not limited to, A/-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso- butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • references to an AT2 receptor agonist include references to compounds that can bind to the AT2 receptor and induce a biological response from the AT2 receptor.
  • a compound of the invention includes AT2 receptor agonists that fully activate and those that partially activate the AT2 receptor and those compounds that can stimulate or activate the AT2 receptor.
  • an AT2 receptor agonist may be defined to include any compound that can stimulate or activate the AT2 receptor.
  • the compound of the invention is an AT2 receptor specific agonist that binds selectively to the AT2 receptor.
  • Particular compounds of the invention include A/-butyloxycarbonyl-3-(4-imidazol-1- ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • Particular compounds of the invention that bind selectively to the AT2 receptor include
  • a compound of the invention for example, the compound A/-butyloxycarbonyl-3-(4-imidazol-1- ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21) or a pharmaceutically acceptable salt (preferably an HCI salt of a compound of the invention), solvate or prodrug thereof, for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • a pharmaceutically acceptable salt preferably an HCI salt of a compound of the invention
  • the compounds of the invention e.g., AT2 receptor agonists, and other compounds that stimulate AT2 receptors
  • pharmaceutically acceptable salts e.g., an HCI salt of the compound of the invention
  • solvates or prodrugs thereof may also be used in the manufacture of a medicament for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • a method for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity comprises administering a compound of the invention or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a subject in need of such treatment.
  • the compound of the invention can be A/-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2- sulfonamide (C21), or a pharmaceutically acceptable salt solvate or prodrug thereof.
  • a particular pharmaceutically acceptable salt of a compound useful in the methods of the invention that may be mentioned includes, but is not limited to, the HCI salt.
  • a further particular pharmaceutically acceptable salt of a compound useful in the methods of the invention that may be mentioned includes the sodium salt.
  • salts include, but are not limited to, acid addition salts and base addition salts.
  • Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of the invention with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo or by freeze-drying). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example, using a suitable ion exchange resin.
  • a pharmaceutically acceptable salt can be a hydrochloric acid salt.
  • a "prodrug” is a composition that undergoes an in vivo modification when administered to a subject, wherein the product of the in vivo modification is a therapeutically effective compound.
  • Prodrugs of compounds may be prepared by, for example, preparing a given compound as an ester. Thus, for example, an esterified form of the compound may be administered to a subject and may be de-esterified in vivo thereby releasing a therapeutically effective compound.
  • some compounds may be prepared as prodrugs by adding short polypeptides (e.g. , 1-6 amino acids) to the compound.
  • prodrugs when administered to a subject may be cleaved (by, e.g., trypsin or other peptidases/proteases) thereby releasing a therapeutically effective compound. Formation of prodrugs is not limited by the specific examples described herein. Other ways of preparing therapeutically effective compounds as prodrugs are known.
  • Compounds of the invention also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.
  • Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation.
  • the various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques.
  • the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation, for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means (e.g. HPLC, chromatography over silica).
  • the compounds of the invention are useful because they possess pharmacological activity.
  • the compounds of the invention are agonists of Ang II, more particularly, they are agonists of the AT2 receptor, and, especially, are selective agonists of that sub- receptor.
  • Compounds of the invention have the advantage that they bind selectively to, and exhibit agonist activity at, the AT2 receptor.
  • the affinity ratio for the relevant compound is at least 50: 1 , at least 100: 1 , preferably at least 1000: 1 , more preferably at least 10000: 1 , and even more preferably at least 25000: 1.
  • the compounds of the invention are useful for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • a method for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity comprises administration of a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt (e.g, an HCI salt of a compound of the invention), solvate or prodrug thereof to a subject suffering from, such a condition.
  • the compound of the invention may be used in a method of preventing cancer treatment-related cardiotoxicity. In another embodiment, the compound of the invention may be used in a method of reducing the risk of cancer treatment-related cardiotoxicity. In a further embodiment, the compound of the invention may be used in a method of reducing the occurrence of cancer treatment-related cardiotoxicity. In a yet further embodiment, the compound of the invention may be used in a method of reducing the severity of cancer treatment-related cardiotoxicity. Cancer treatment-related cardiotoxicity includes one or more symptoms as are hereinbefore described. In preferred embodiments, the cancer treatment-related cardiotoxicity is LVD or heart failure.
  • Cancer treatment-related cardiotoxicity includes any cardiotoxicity associated with the treatment of cancer resulting from or associated with the use of a known anti-cancer therapy, such as therapy using anthracyclines (e.g. doxorubicin), 5-fluorourcil, taxanes (e.g. paclitaxel), vinca alkaloids, cyclophosphamide, trastuzumab, tamoxifen, bevacizumab, or COX-2 specific inhibitors.
  • anthracyclines e.g. doxorubicin
  • 5-fluorourcil e.g. paclitaxel
  • vinca alkaloids cyclophosphamide
  • trastuzumab e.g. paclitaxel
  • tamoxifen e.g. paclitaxel
  • COX-2 specific inhibitors e.g. doxorubicin
  • the cancer treatment-related cardiotoxicity is a cardiotoxicity resulting from or associated with treatment using an anthr
  • the compound of the invention (e.g. C21) may be used in a method of preventing or reducing the severity of LVD or heart failure in a patient who has been treated, is being treated or will be treated for cancer using an anthracycline-based therapy, such as doxorubicin.
  • an anthracycline-based therapy such as doxorubicin.
  • the compounds of the invention will normally be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, by any other parenteral route or via inhalation, in a pharmaceutically acceptable dosage form. Additional methods of administration include but are not limited to intraarterial administration, intramuscular administration, intraperitoneal administration, intraportal administration, intradermal administration, epidural administration, and/or intrathecal administration.
  • the compounds of the invention may be administered alone, but are preferably administered by way of known pharmaceutical formulations, including tablets (e.g. tablets for oral administration), capsules (e.g. capsules for oral administration), elixirs (e.g. elixirs for oral administration), suppositories (e.g. suppositories for rectal administration), sterile solutions (e.g. sterile solutions for parenteral administration or sterile solutions for intramuscular administration), or sterile suspensions (e.g. sterile suspensions for parenteral administration or sterile suspensions intramuscular administration), and the like.
  • Such formulations may be prepared in accordance with standard and/or accepted pharmaceutical practice.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the molecule with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Formulations in accordance with the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycolate, cross-linked povidone, cross- linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
  • Molded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethylcellulose in varying proportions to provide desired release profile.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
  • a pharmaceutical formulation comprising a compound of the invention, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for use for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • Acceptable carriers and diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro ed. 1985).
  • the choice of pharmaceutical carriers and diluents can be selected with regard to the intended route of administration and standard pharmaceutical practice.
  • the pharmaceutical formulations may comprise as, or in addition to, the carriers and diluents any suitable binder, lubricant, suspending agent, coating agent, or solubilising agent. Preservatives, stabilisers, dyes and even flavouring agents may be provided in the pharmaceutical formulation.
  • Compounds of the invention may also be administered in combination with other AT2 agonists that are known in the art, as well as in combination with AT1 receptor antagonists that are known in the art, such as losartan or candesartan, and/or in combination with an inhibitor of angiotensin converting enzyme (ACE), such as enalapril or ramipril
  • ACE angiotensin converting enzyme
  • Such combinations may therefore be useful for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity in the therapeutic.
  • Non-limiting but illustrative examples of AT1 receptor antagonists that can be used according to the embodiments include azilsartan, candesartan, eprosartan, fimasartan, irbesartan, losartan, milfasartan, olmesartan, pomisartan, pratosartan, ripiasartan, saprisartan, tasosartan, telmisartan, valsartan and/or combinations thereof.
  • Non-limiting but illustrative examples of ACE inhibitors that can be used according to the embodiments include captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, fosinopril, moexipril, cilazapril, spirapril, temocapril, alacepril, ceronapril, delepril, moveltipril, and/or combinations thereof.
  • angiotensin II receptor agonist and/or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, and at least one angiotensin II type 1 (AT1) receptor antagonist in the manufacture of a medicament for preventing/reducing the risk of/reducing the occurrence of/ reducing the severity of cardiotoxicity associated with cancer treatment.
  • AT1 angiotensin II type 1
  • composition comprising at least one angiotensin II type 1 (AT1) receptor antagonist for use in preventing/reducing the risk of/reducing the occurrence of/ reducing the severity of cardiotoxicity associated with cancer treatment, wherein the at least one angiotensin II type 1 (AT1) receptor antagonist is administered in combination with at least one angiotensin II receptor agonist, and/or a pharmaceutically acceptable salt, solvate and/or prodrug thereof; and
  • angiotensin II type 1 (AT1) receptor antagonist in the manufacture of a medicament for preventing/reducing the risk of/reducing the occurrence of/ reducing the severity of cardiotoxicity associated with cancer treatment, wherein the medicament is administered either concomitantly or sequentially with at least one angiotensin II receptor agonist, and/or a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
  • AT1 angiotensin II type 1
  • angiotensin II receptor agonist and/or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, and at least one inhibitor of angiotensin converting enzyme (ACE) in the manufacture of a medicament for preventing/reducing the risk of/reducing the occurrence of/ reducing the severity of cardiotoxicity associated with cancer treatment.
  • ACE angiotensin converting enzyme
  • composition comprising at least one inhibitor of angiotensin converting enzyme (ACE) for use in preventing/reducing the risk of/reducing the occurrence of/ reducing the severity of cardiotoxicity associated with cancer treatment, wherein the at least one inhibitor of angiotensin converting enzyme (ACE) is administered in combination with at least one angiotensin II receptor agonist, and/or a pharmaceutically acceptable salt, solvate and/or prodrug thereof; and
  • ACE angiotensin converting enzyme
  • the angiotensin II receptor agonist is preferably an angiotensin II type 2 (AT2) receptor agonist.
  • a combination product comprising:
  • A an AT2 receptor agonist and/or a compound that stimulates AT2 receptors, and ⁇
  • B an AT1 receptor antagonist, and/or an ACE inhibitor
  • each of components (A) and (B) is formulated in admixture with a pharmaceutically- acceptable adjuvant, diluent or carrier, for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • Such combination products provide for the administration of an AT2 receptor agonist and/or a compound that stimulates an AT2 receptor (as defined herein), in conjunction with an AT1 receptor antagonist and/or an ACE inhibitor, and may thus be presented either as separate formulations, wherein at least one of those formulations comprises an AT2 receptor agonist or a compound that stimulates an AT2 receptor (as defined herein, e.g., a compound of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof), and at least one formulation comprises an AT1 receptor antagonist and/or an ACE inhibitor, or may be presented (i.e., formulated) as a combined preparation (i.e., presented as a single formulation including an AT2 receptor agonist and/or a compound that stimulates an AT2 receptor together with either an AT1 receptor antagonist or an ACE inhibitor (or both)).
  • a combined preparation i.e., presented as a single formulation including an AT2 receptor agonist and/or a compound that stimulates an AT2 receptor together with either an
  • a pharmaceutical formulation comprising an AT2 receptor agonist and/or a compound that stimulates an AT2 receptor (e.g., a compound of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof) and an AT1 receptor antagonist or an ACE inhibitor in admixture with a pharmaceutically-acceptable adjuvant, diluent and/or carrier, for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity; and
  • a pharmaceutical formulation comprising an AT2 receptor agonist and/or a compound that stimulates an AT2 receptor (e.g., a compound of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof), in admixture with a pharmaceutically-acceptable adjuvant, diluent and/or carrier; and
  • components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other, for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • the compounds of the invention may be administered at varying doses.
  • suitable daily doses are in the range of about 1 to 1000 mg (e.g., about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 75 mg, 100, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg, and the like, or any range or value therein) per subject, administered in single or multiple doses.
  • about 1 to 1000 mg e.g., about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 75 mg, 100, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350
  • More preferred daily doses are in the range 2.5 to 250 mg (e.g., about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 1 10 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, or about 250 mg and the like or any range or value therein) per subject.
  • Individual doses of compounds of the invention may be in the range 1 to 100 mg (e.g., about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg , about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85mg, about 90 mg, about 95 mg, or about 100 mg, and the like, or any range or values therein).
  • compounds of the present invention may be administered in single doses, e.g. once daily or more seldom, or in a total daily dosage administered in divided doses of two, three or four times daily.
  • physician, or the skilled person will be able to determine the actual dosage which will be most suitable for an individual subject, which is likely to vary with the condition that is to be treated, as well as the age, weight, sex and response of the particular subject to be treated.
  • the above-mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • the compounds of the present invention may be administered over a period of at least two days; for example, at least three days, or at least four days, or at least five days, or at least six days, or at least seven days (i.e. one week), or at least eight days, or at least nine days, or at least ten days, or at least 1 1 days, or at least 12 days, or at least 13 days, or at least 14 days (i.e.
  • the compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile (e.g., higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties than compounds known in the prior art.
  • Such effects may be evaluated clinically, objectively and/or subjectively by a health care professional, a treatment subject or an observer.
  • a method for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity of in a subject in need thereof comprising: administering to said subject a therapeutically effective amount of an angiotensin II (AT2) receptor agonist and/or a pharmaceutically acceptable salt, solvate, solvate of a pharmaceutically acceptable salt, or prodrug thereof, thereby for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity in said subject.
  • the AT2 receptor agonist is an AT2 specific agonist.
  • the AT2 receptor agonist is A/-butyloxycarbonyl-3-(4-imidazol-1- ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21) or a pharmaceutically acceptable salt, solvate, solvate of pharmaceutically acceptable salt, or prodrug thereof.
  • the AT2 receptor agonist is the compound depicted in Structure 1.
  • the method comprises administering to said subject a therapeutically effective amount of an AT1 receptor antagonist and/or an angiotensin converting enzyme (ACE) inhibitor.
  • the AT2 receptor agonist is provided in the same composition or pharmaceutical formulation as the AT1 receptor antagonist and/or the ACE inhibitor.
  • AT2 receptor agonist is provided in a different formulation from the AT1 receptor antagonist and/or the ACE inhibitor and the separate formulations are administered to the subject simultaneously, sequentially or separately.
  • the composition or pharmaceutical formulation comprises a pharmaceutically-acceptable adjuvant, diluent and/or carrier.
  • administering comprises oral administration, intravenous administration, subcutaneous administration, buccal administration, rectal administration, dermal administration, nasal administration, tracheal administration, bronchial administration, inhalation administration, intraarterial administration, intramuscular administration, intraperitoneal administration, intraportal administration, intradermal administration, epidural administration, and/or intrathecal administration.
  • the present invention provides a kit for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity, comprising a pharmaceutical formulation comprising AT2 receptor agonist.
  • the kit further comprises a pharmaceutical formulation comprising an AT1 receptor antagonist and/or an ACE inhibitor.
  • the kit further comprises instructions for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity for with an effective amount of the pharmaceutical formulation.
  • the kit further comprises an AT2 receptor agonist that is the AT2 receptor agonist depicted in Structure 1.
  • a compound for use for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity wherein the compound is an AT2 receptor agonist, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • the use of a compound in the manufacture of a medicament for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity is provided, wherein the compound is an AT2 receptor agonist, or a pharmaceutically acceptable salt, solvate or prodrug thereof.
  • a method for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity comprising the administration of a compound which is an AT2 receptor agonist, or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need of such therapy.
  • the compound is a compound which is capable of stimulating AT2 receptors.
  • the compound is a compound that binds selectively to the AT2 receptor.
  • the compound is A/-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5- / ' so-butylthiophene-2-sulfonamide.
  • a pharmaceutical formulation comprising a compound of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • a pharmaceutical formulation comprising a compound of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and an AT1 receptor antagonist, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • kit of parts comprising components:
  • components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other, for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • a pharmaceutical formulation including a compound of the invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and an angiotensin converting enzyme inhibitor, in admixture with a pharmaceutically- acceptable adjuvant, diluent or carrier, for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • kit of parts comprising components:
  • a pharmaceutical formulation including an angiotensin converting enzyme inhibitor in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other, for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • the present invention provides an AT2 receptor agonist as described herein, an AT2 receptor agonist for use as described herein, pharmaceutical formulation as described herein, pharmaceutical formulation for use as described herein, a use as described herein, a method as described herein, a compound as described herein, a compound for use as described herein, a combination product as described herein, a combination product for use as described herein, a kit-of-parts as described herein, a kit-of- parts for use as described herein for prevention/reduction of the risk/reduction of the occurrence/reduction of the severity of cancer treatment-related cardiotoxicity.
  • Example 1 The effect of angiotensin li type 2 receptor agonist C21 , with or without combination with losartan, on doxorubicin induced heart failure
  • Aim In heart failure, most deleterious effects of the renin-angiotensin system on the cardiovascular system are mediated by angiotensin (AT) II type 1 -receptors. However, ATI I type 2-receptors have a capability to compensate or antagonize these deleterious effects.
  • AT angiotensin
  • DOX cancer- medication doxorubicin
  • LVED Left ventricle enddiastolic volume
  • LVES Left ventricle endsystolic volume
  • LV EF Left ventricle ejection fraction.
  • the AT II type 2-receptor agonist C21 attenuates the deleterious effects of the renin-angiotensin system on heart failure, to an extent similar to the AT II type-1 receptor antagonist losartan, and the most pronounced protective effect was seen after a combination of the two drugs.
  • preventive treatment with C21 alone or in combination with a AT1 receptor antagonist (such as losartan) represents a novel approach for patients to prevent cardiotoxicity induced by the cancer-medication doxorubicin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La présente invention concerne une nouvelle utilisation de composés qui sont des agonistes de l'angiotensine II (Ang II), plus particulièrement des agonistes du récepteur de type 2 de l'Ang II (récepteur AT2), et spécifiquement des agonistes qui se lient au récepteur AT2 pour prévenir ou réduire le risque de la cardiotoxicité liée aux traitements du cancer.
PCT/GB2017/051821 2016-06-21 2017-06-21 Méthodes et compositions pour prévenir ou réduire, le risque de cardiotoxicité liée aux traitements du cancer. WO2017221012A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352821P 2016-06-21 2016-06-21
US62/352,821 2016-06-21

Publications (1)

Publication Number Publication Date
WO2017221012A1 true WO2017221012A1 (fr) 2017-12-28

Family

ID=59388102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2017/051821 WO2017221012A1 (fr) 2016-06-21 2017-06-21 Méthodes et compositions pour prévenir ou réduire, le risque de cardiotoxicité liée aux traitements du cancer.

Country Status (1)

Country Link
WO (1) WO2017221012A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053344A1 (fr) 2019-09-20 2021-03-25 Vicore Pharma Ab Nouveaux composés
WO2021105695A1 (fr) 2019-11-28 2021-06-03 Vicore Pharma Ab Nouvelle utilisation d'un agoniste du récepteur de l'angiotensine ii
WO2021186185A1 (fr) 2020-03-19 2021-09-23 Vicore Pharma Ab Nouveaux composés utiles dans le traitement et/ou la prévention d'une maladie, d'un trouble ou d'un état de santé associé à l'angiotensine ii
WO2021186180A1 (fr) 2020-03-20 2021-09-23 Vicore Pharma Ab Carbamates d'imidazolyle thiophene sulfonyle destinés à être utilisés dans le traitement de maladies associées à l'angiotensine ii
WO2021214486A1 (fr) * 2020-04-24 2021-10-28 Vicore Pharma Ab Nouvelle composition de capsule pour administration perorale
WO2022049372A1 (fr) 2020-09-01 2022-03-10 Vicore Pharma Ab Nouveaux composés destinés à être utilisés dans le traitement de maladies associées à l'angiotensine ii
WO2022200785A1 (fr) 2021-03-23 2022-09-29 Vicore Pharma Ab Ligands sélectifs du récepteur de l'angiotensine ii
WO2022200787A1 (fr) 2021-03-23 2022-09-29 Vicore Pharma Ab Ligands sélectifs du récepteur de l'angiotensine ii
WO2022200786A1 (fr) 2021-03-23 2022-09-29 Vicore Pharma Ab Ligands sélectifs du récepteur de l'angiotensine ii
WO2023281271A1 (fr) 2021-07-09 2023-01-12 Vicore Pharma Ab Nouveaux composés sélectifs de l'angiotensine ii
US11654115B2 (en) 2020-04-24 2023-05-23 Vicore Pharma Ab Delayed release composition for peroral administration
US11844868B2 (en) 2020-04-24 2023-12-19 Vicore Pharma Ab Dry powder composition for peroral administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043339A1 (fr) 1998-02-24 1999-09-02 A+ Science Invest Ab Preparation pharmaceutique comprenant un agoniste du recepteur de l'angiotensine ii type 2 et son utilisation
WO2002096883A1 (fr) 2001-05-31 2002-12-05 Vicore Pharma Ab Composes tricycliques utiles comme agonistes de l'angiotensine ii

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043339A1 (fr) 1998-02-24 1999-09-02 A+ Science Invest Ab Preparation pharmaceutique comprenant un agoniste du recepteur de l'angiotensine ii type 2 et son utilisation
WO2002096883A1 (fr) 2001-05-31 2002-12-05 Vicore Pharma Ab Composes tricycliques utiles comme agonistes de l'angiotensine ii

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING CO.
CARDINALE D., CIRCULATION, vol. 114, no. 23, 5 December 2006 (2006-12-05), pages 2474 - 81
DE GASPARO M ET AL., PHARMACOL REV, vol. 52, 2000, pages 415 - 472
E. KASCHINA ET AL: "Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?", CIRCULATION, vol. 118, no. 24, 9 December 2008 (2008-12-09), pages 2523 - 2532, XP055080309, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.108.784868 *
FLORESCU M. ET AL., MAEDICA (BUCHAR, vol. 8, no. 1, March 2013 (2013-03-01), pages 59 - 6
REHMAN ASIA; LEIBOWITZ AVSHALOM; YAMAMOTO NAOKI; RAUTUREAU YOHANN; PARADIS PIERRE; SCHIFFRIN ERNESTO L: "Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats.(+ Online Supplement)", HYPERTENSION, vol. 59, no. 2, 19 December 2011 (2011-12-19), pages 291 - 299,1-11, XP002773454, DOI: 10.1161/HYPERTENSIONAHA.111.180158 *
SÃ CR BASTIEN FOULQUIER ET AL: "Impact of the ATReceptor Agonist C21 on Blood Pressure and Beyond", CURRENT HYPERTENSION REPORTS, CURRENT SCIENCE INC, NEW YORK, vol. 14, no. 5, 27 July 2012 (2012-07-27), pages 403 - 409, XP035107326, ISSN: 1534-3111, DOI: 10.1007/S11906-012-0291-6 *
VERDONK KOEN ET AL: "Angiotensin II type 2 receptor agonists: where should they be applied?", EXPERT OPINION ON INVESTIGATIONAL D, INFORMA HEALTHCARE, UK, vol. 21, no. 4, 1 April 2012 (2012-04-01), pages 501 - 513, XP009179572, ISSN: 1354-3784, DOI: 10.1517/13543784.2012.664131 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053344A1 (fr) 2019-09-20 2021-03-25 Vicore Pharma Ab Nouveaux composés
WO2021105695A1 (fr) 2019-11-28 2021-06-03 Vicore Pharma Ab Nouvelle utilisation d'un agoniste du récepteur de l'angiotensine ii
WO2021186185A1 (fr) 2020-03-19 2021-09-23 Vicore Pharma Ab Nouveaux composés utiles dans le traitement et/ou la prévention d'une maladie, d'un trouble ou d'un état de santé associé à l'angiotensine ii
WO2021186180A1 (fr) 2020-03-20 2021-09-23 Vicore Pharma Ab Carbamates d'imidazolyle thiophene sulfonyle destinés à être utilisés dans le traitement de maladies associées à l'angiotensine ii
WO2021214486A1 (fr) * 2020-04-24 2021-10-28 Vicore Pharma Ab Nouvelle composition de capsule pour administration perorale
US11654115B2 (en) 2020-04-24 2023-05-23 Vicore Pharma Ab Delayed release composition for peroral administration
US11844868B2 (en) 2020-04-24 2023-12-19 Vicore Pharma Ab Dry powder composition for peroral administration
WO2022049372A1 (fr) 2020-09-01 2022-03-10 Vicore Pharma Ab Nouveaux composés destinés à être utilisés dans le traitement de maladies associées à l'angiotensine ii
WO2022200785A1 (fr) 2021-03-23 2022-09-29 Vicore Pharma Ab Ligands sélectifs du récepteur de l'angiotensine ii
WO2022200787A1 (fr) 2021-03-23 2022-09-29 Vicore Pharma Ab Ligands sélectifs du récepteur de l'angiotensine ii
WO2022200786A1 (fr) 2021-03-23 2022-09-29 Vicore Pharma Ab Ligands sélectifs du récepteur de l'angiotensine ii
WO2023281271A1 (fr) 2021-07-09 2023-01-12 Vicore Pharma Ab Nouveaux composés sélectifs de l'angiotensine ii

Similar Documents

Publication Publication Date Title
WO2017221012A1 (fr) Méthodes et compositions pour prévenir ou réduire, le risque de cardiotoxicité liée aux traitements du cancer.
US20180078529A1 (en) Angiotensin ii receptor agonist for treating pulmonary fibrosis
EP3038654B1 (fr) Nouvelle utilisation
KR20150046039A (ko) 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제
JP2012025756A (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
EP3153170A1 (fr) Méthode d'utilisation de dérivés de la quinoléine pour le traitement des sarcomes des tissus mous, applications et composition pharmaceutique les contenant destinée au traitement des sarcomes des tissus mous
CA2415826A1 (fr) Polytherapie par antagoniste d'aldosterone epoxy-steroidien et inhibiteur calcique pour le traitement de l'insuffisance cardiaque congestive
CA2997671A1 (fr) Polytherapies pour le traitement du cancer
WO2016107879A2 (fr) Nouvelle utilisation d'agonistes du récepteur de l'angiotensine ii
CN115531547B (zh) 一种具有预防、缓解或治疗急性髓系白血病功效的联合用药物组合物及其应用
US11931341B2 (en) Compositions and methods for the treatment and prevention of muscular dystrophy
WO2017006254A1 (fr) Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes
US20100152305A1 (en) Methods of treatment of hyperuricemia and associated disease states
TW201313679A (zh) 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
US20220265776A1 (en) Combination
EP2694074B1 (fr) Utilisation d'antagonistes de récepteur d'adénosine a2b pour traiter l'insuffisance cardiaque et l'arythmie chez des patients post-infarctus du myocarde
PT1587584E (pt) Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais
EP3946367A1 (fr) Canagliflozine pour le traitement de patients diabétiques avec une maladie rénale chronique
JP2002535367A (ja) 急性心筋梗塞の処置のためのアンギオテンシンｉｉレセプターアンタゴニストの使用
CZ300888B6 (cs) Lécivo pro lécení srdecního selhání obsahující antagonistu kortizolu
CA3142325A1 (fr) Compositions et methodes de traitement d'une maladie metabolique
US9433603B2 (en) Use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation
JP5485704B2 (ja) 骨吸収と骨形成の不均衡を是正するための方法ならびにキット及び組成物
AU2019200876A1 (en) Panobinostat dosages for multiple myeloma
EP2793878A1 (fr) Association d'acide (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonique) et d'un second agent antihypertensive

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17743069

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17743069

Country of ref document: EP

Kind code of ref document: A1